Language:

Heart failure

Lancet, 2005-05, Vol.365 (9474), p.1877-1889 [Peer Reviewed Journal]

2005 Elsevier Ltd ;2005 INIST-CNRS ;Copyright Lancet Ltd. May 28-Jun 3, 2005 ;ISSN: 0140-6736 ;EISSN: 1474-547X ;DOI: 10.1016/S0140-6736(05)66621-4 ;PMID: 15924986 ;CODEN: LANCAO

Full text available

Citations Cited by

Actions
1. Add to My Research
2. Remove from My Research
3. E-mail
4. Print
5. Permalink
6. Citation
7. EasyBib
8. EndNote
9. RefWorks
10. Delicious
11. Export RIS
12. Export BibTeX

Title:
Heart failure
Author: McMurray, John JV ; Pfeffer, Marc A
Subjects: Biological and medical sciences ; Cardiology. Vascular system ; Epidemiology ; General aspects ; Health risk assessment ; Heart ; Heart failure ; Heart Failure - complications ; Heart Failure - diagnosis ; Heart Failure - physiopathology ; Heart Failure - therapy ; Heart failure, cardiogenic pulmonary edema, cardiac enlargement ; Humans ; Medical diagnosis ; Medical sciences ; Medical treatment ; Ventricular Dysfunction, Left - physiopathology
Is Part Of: Lancet, 2005-05, Vol.365 (9474), p.1877-1889
Description: Although heart failure is common, disabling, and deadly, there are now many effective treatments, at least for patients with low left-ventricular ejection fraction. For all, angiotensin-converting-enzyme inhibitors and β blockers are the essential disease-modifying treatments, improving symptoms, reducing hospital admissions, and increasing survival. Implantable cardioverter defibrillators also improve survival. For patients with persistent symptoms, angiotensin-receptor blockers and aldosterone antagonists have additional benefits. These treatments are now preferred to digoxin, although this drug can still be useful at an earlier stage in patients with atrial fibrillation. In some patients with persistently severe symptoms and a wide QRS on the electrocardiogram, cardiac resynchronisation therapy also reduces mortality and morbidity. The role of other markers of ventricular dys-synchrony is under investigation. There is growing evidence that left-ventricular assist devices are indicated in some patients with end-stage heart failure. Organised delivery of care also improves outcome. However, there is still no firmly evidence-based treatment for heart failure with preserved ejection fraction. Many new pharmacological, device, and surgical treatments for heart failure are currently under evaluation in clinical trials, and other approaches, including stem-cell treatment, are at an earlier stage of investigation.
Publisher: London: Elsevier Ltd
Language: English
Identifier: ISSN: 0140-6736
EISSN: 1474-547X
DOI: 10.1016/S0140-6736(05)66621-4
PMID: 15924986
CODEN: LANCAO
Source: ProQuest One Psychology
MEDLINE
ProQuest Central

Back to results list


INSPIRE LIBRARY - TON DUC THANG UNIVERSITY	(84-028) 37 755 057	Feedback
19 Nguyen Huu Tho St. Dist.7, HCM	thuvien@tdtu.edu.vn	Feedback

Heart failure

2005 Elsevier Ltd ;2005 INIST-CNRS ;Copyright Lancet Ltd. May 28-Jun 3, 2005 ;ISSN: 0140-6736 ;EISSN: 1474-547X ;DOI: 10.1016/S0140-6736(05)66621-4 ;PMID: 15924986 ;CODEN: LANCAO

Searching Remote Databases, Please Wait